Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Mass spectrometry shows extra peaks beyond retatrutide and cagrilintide
BMI 30.0 kg m 2 or 27.0 kg m 2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease
While safety monitoring was comprehensive, the trials were not specifically designed to detect rare adverse effects that might occur at rates lower than 1-2%, which would require much larger participant numbers
PlexusDx recommends keeping this information accessible for reference
US$ 21.60
US$ 20.70
US$ 25.59
US$ 20.68
US$ 21.03
